# A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer

> **NCT05170594** · PHASE2 · UNKNOWN · sponsor: **The Second Affiliated Hospital of Shandong First Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** chemotherapy
- **DRUG:** Fluzoparib

## Key facts

- **NCT ID:** NCT05170594
- **Lead sponsor:** The Second Affiliated Hospital of Shandong First Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-24
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05170594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05170594, "A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05170594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*